Stryker is releasing its new Trevo Pro Retriever for removing blood clots from arteries in the brain during acute ischemic strokes.
The device, which features Stentriever Technology, was trialed against the company’s Merci Retriever and showed significantly more success at revascularizing occluded vessels.
The Trevo® Pro Retriever demonstrated strong clinical results in the TREVO 2 clinical trial presented at the 2012 European Stroke Conference in May. This technology demonstrated the highest rate of revascularization in a randomized embolectomy stroke device trial, and achieved significantly better post-procedure revascularization than the Merci Retriever® (92% in the Trevo®Retriever arm compared to 76.7% in the Merci Retriever® arm). Other measures of performance also strongly favored the Trevo® Pro Retriever, including improvement in the National Institutes of Health Stroke Scale (NIHSS) score, excellent composite safety endpoints and shorter hospital stays.
Press release: STRYKER ANNOUNCES FDA CLEARANCE OF TREVO® PRO RETRIEVAL SYSTEM…